Clinical Scorecard: A Population-Based Analysis of Osteosarcoma and Ewing Sarcoma in the Skull Among Pediatric and Adolescent Patients
At a Glance
Category
Detail
Condition
Primary malignant skull tumors: osteosarcoma (OSC) and Ewing sarcoma (EWS)
Key Mechanisms
Rare occurrence in skull; OSC typically affects long bones; EWS usually targets pelvis and long bones; skull involvement poses diagnostic and treatment challenges due to proximity to vital structures
Target Population
Pediatric and adolescent patients aged 0–19 years with primary OSC or EWS of the skull
Care Setting
Specialized oncology centers with access to multimodal treatment and population-based cancer registries
Key Highlights
Study analyzed 124 pediatric and adolescent patients with OSC or EWS of the skull from SEER database (2000–2019).
Overall survival rates were 90.3% at 1 year, 77.9% at 3 years, and 75.6% at 5 years.
Age, histological subtype, and SEER stage were independent prognostic factors for overall survival.
Guideline-Based Recommendations
Diagnosis
Histopathological confirmation of OSC or EWS of the skull is essential.
Use SEER staging to classify disease as localized, regional, or distant.
Exclude metastatic tumors from other sites to confirm primary skull origin.
Management
Surgical resection is the primary treatment modality, performed in approximately 85% of cases.
Chemotherapy is administered in conjunction with surgery in about 85% of patients.
Radiotherapy is more frequently used in Ewing sarcoma than osteosarcoma (approximately 44% overall).
Monitoring & Follow-up
Regular follow-up to assess overall survival and detect disease progression.
Monitor patients closely based on age group and disease stage due to prognostic implications.
Risks
Older adolescents (15–19 years) have higher mortality risk compared to younger children (0–14 years).
Distant metastatic disease at diagnosis significantly increases mortality risk.
Osteosarcoma subtype is associated with poorer prognosis compared to Ewing sarcoma.
Patient & Prescribing Data
Pediatric and adolescent patients (0–19 years) with primary skull osteosarcoma or Ewing sarcoma
High utilization of surgery and chemotherapy; radiotherapy used more in Ewing sarcoma; treatment decisions influenced by tumor subtype and stage
Clinical Best Practices
Ensure comprehensive histopathological diagnosis and staging to guide treatment.
Prioritize surgical resection combined with chemotherapy for optimal outcomes.
Consider radiotherapy particularly in Ewing sarcoma cases.
Stratify patients by age and stage to tailor prognosis and follow-up intensity.
Use population-based data to inform clinical decision-making for these rare tumors.
Join UCI Health at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 to June 2 in Chicago, as we showcase how Orange County’s only academic health system is advancing the future of cancer care.
